We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

58 hedge funds and large institutions have $12.7M invested in ImmunityBio in 2019 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 15 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 15

27% more capital invested

Capital invested by funds: $9.95M → $12.7M (+$2.73M)

0.73% less ownership

Funds ownership: 10.83% → 10.1% (-0.73%)

5% less funds holding

Funds holding: 61 → 58 (-3)

17% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 12

36% less call options, than puts

Call options by funds: $83K | Put options by funds: $130K

Holders
58
Holders Change
-3
Holders Change %
-4.92%
% of All Funds
1.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
20
Reduced
15
Closed
12
Calls
$83K
Puts
$130K
Net Calls
-$47K
Net Calls Change
-$57K

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$195K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$157K
3
TCIM
TIAA CREF Investment Management
New York
+$86.2K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$74.7K
5
OAM
Oxford Asset Management
United Kingdom
+$71K

Top Sellers

1
CS
Candriam SCA
Luxembourg
-$270K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$210K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$208K
4
Deutsche Bank
Deutsche Bank
Germany
-$144K
5
Millennium Management
Millennium Management
New York
-$102K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$2.7M -$44.8K -35,640 -2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$2.15M +$157K +125,280 +10%
Renaissance Technologies
3
Renaissance Technologies
New York
$1.95M +$195K +155,000 +14%
WCM
4
Wildcat Capital Management
New York
$879K – – –
State Street
5
State Street
Massachusetts
$654K +$3.38K +2,692 +0.7%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$539K +$15.7K +12,492 +4%
Northern Trust
7
Northern Trust
Illinois
$455K +$4.41K +3,509 +1%
HKAM
8
Horizon Kinetics Asset Management
New York
$410K +$326K +259,420 New
Dimensional Fund Advisors
9
Dimensional Fund Advisors
Texas
$355K -$5.91K -4,709 -2%
BCM
10
Bridgeway Capital Management
Texas
$318K -$62.8K -50,000 -20%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$254K +$74.7K +59,473 +59%
Charles Schwab
12
Charles Schwab
California
$216K +$3.37K +2,686 +2%
JP Morgan Chase
13
JP Morgan Chase
New York
$216K +$27.7K +22,031 +19%
TCIM
14
TIAA CREF Investment Management
New York
$186K +$86.2K +68,686 +139%
OAM
15
Oxford Asset Management
United Kingdom
$144K +$71K +56,585 +164%
DekaBank Deutsche Girozentrale
16
DekaBank Deutsche Girozentrale
Germany
$107K +$7.53K +6,000 +23%
Simplex Trading
17
Simplex Trading
Illinois
$93K +$56.8K +45,217 +322%
TA
18
Teachers Advisors
New York
$88K – – –
California State Teachers Retirement System (CalSTRS)
19
California State Teachers Retirement System (CalSTRS)
California
$77K – – –
AllianceBernstein
20
AllianceBernstein
Tennessee
$73K -$7.41K -5,900 -11%
RhumbLine Advisers
21
RhumbLine Advisers
Massachusetts
$60K -$239 -190 -0.5%
State of Wisconsin Investment Board
22
State of Wisconsin Investment Board
Wisconsin
$60K +$10.8K +8,600 +30%
Millennium Management
23
Millennium Management
New York
$59K -$102K -81,018 -69%
Deutsche Bank
24
Deutsche Bank
Germany
$54K -$144K -114,474 -77%
OC
25
Oppenheimer & Co
New York
$52K – – –
1
2 3

IBRX Hedge Fund Activity: Q1 2019 in Review

58 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q1 2019, worth a combined $12.7M — up 27% from $9.95M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of IBRX and 10 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 20 added.

The largest buyer was Renaissance Technologies, adding an estimated $195K. The largest seller was Candriam SCA, exiting entirely with an estimated $270K sold.

  • 58 institutional investors held ImmunityBio (IBRX) as of Q1 2019, down from 61 in Q4 2018.
  • Funds reported $12.7M of ImmunityBio stock for Q1 2019, up 27% quarter-over-quarter.
  • 10 funds opened new ImmunityBio positions in Q1 2019 and 12 closed out, a net change of -2 holders.
  • The largest ImmunityBio buyer in Q1 2019 was Renaissance Technologies, an estimated $195K added.
  • The largest ImmunityBio seller in Q1 2019 was Candriam SCA, an estimated $270K sold.

Based on aggregated 13F filings for Q1 2019.